Ewing Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Buy Report View Sample

Published: October 31, 2022 Report Code: GDGMDHC22381IDB-ST

Report Overview
Key Players
Table of Contents
Table
Figures
FAQs

Ewing Sarcoma Pipeline Drugs Market Report Overview

Ewing’s sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing’s sarcoma can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. The Ewing Sarcoma pipeline drugs market research report provides comprehensive information on the therapeutics under development for Ewing Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.

Ewing Sarcoma Pipeline Drugs Market Segmentation by Targets

The key targets of the Ewing Sarcoma pipeline drugs market are Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, Mast/Stem Cell Growth Factor Receptor Kit, Vascular Endothelial Growth Factor Receptor 1, DNA, DNA Topoisomerase I, and Fibroblast Growth Factor Receptor 1.

Ewing Sarcoma Pipeline Drugs Market Analysis, by Targets

For more target insights on the Ewing Sarcoma pipeline drugs market, download a free report sample

Ewing Sarcoma Pipeline Drugs Market Segmentation by Mechanism of Actions

The key mechanism of actions of the Ewing Sarcoma pipeline drugs market are Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, DNA Topoisomerase I Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, DNA Synthesis Inhibitor, and Fibroblast Growth Factor Receptor 1 Inhibitor.

Ewing Sarcoma Pipeline Drugs Market Analysis, by Mechanisms of Action

For more mechanisms of action insights into the Ewing Sarcoma pipeline drugs market, download a free report sample

Ewing Sarcoma Pipeline Drugs Market Segmentation by Routes of Administration

The key route of administration in the Ewing Sarcoma pipeline drugs market are intravenous, oral, parenteral, intradermal, intravenous drip, intratumor, subcutaneous, and intraperitoneal.

Ewing Sarcoma Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights on the Ewing Sarcoma pipeline drugs market, download a free report sample

Ewing Sarcoma Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Ewing Sarcoma pipeline drugs market are small molecule, monoclonal antibody, monoclonal antibody conjugated, cell therapy, gene-modified cell therapy, fusion protein, and oncolytic virus.

Ewing Sarcoma Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the Ewing Sarcoma pipeline drugs market, download a free report sample

Ewing Sarcoma Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the Ewing Sarcoma pipeline drugs market are Pharma Mar SA, Gradalis Inc, Pfizer Inc, Bristol-Myers Squibb Co, Advenchen Laboratories LLC, Amgen Inc, Bayer AG, and Eisai Co Ltd.

Ewing Sarcoma Pipeline Drugs Market Analysis, by Companies

To know more about the companies in the Ewing Sarcoma pipeline drugs market, download a free report sample

Ewing Sarcoma Pipeline Drugs Market Report Overview

Key Targets	Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, Mast/Stem Cell Growth Factor Receptor Kit, Vascular Endothelial Growth Factor Receptor 1, DNA, DNA Topoisomerase I, and Fibroblast Growth Factor Receptor 1
Key Mechanism of Actions	Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, DNA Topoisomerase I Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, DNA Synthesis Inhibitor, and Fibroblast Growth Factor Receptor 1 Inhibitor
Key Routes of Administration	Intravenous, Oral, Parenteral, Intradermal, Intravenous Drip, Intratumor, Subcutaneous, and Intraperitoneal
Key Molecule Types	Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Cell Therapy, Gene-Modified Cell Therapy, Fusion Protein, and Oncolytic Virus
Leading Companies	Pharma Mar SA, Gradalis Inc, Pfizer Inc, Bristol-Myers Squibb Co, Advenchen Laboratories LLC, Amgen Inc, Bayer AG, and Eisai Co Ltd

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Ewing Sarcoma (Oncology).
The pipeline guide reviews pipeline therapeutics for Ewing Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several development stages ranging from pre-registration to discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products, including product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Ewing Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Ewing Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Ewing Sarcoma (Oncology)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ewing Sarcoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ewing Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

A2A Pharmaceuticals Inc
Aadi Bioscience Inc
Actuate Therapeutics Inc
ADC Therapeutics SA
Advenchen Laboratories LLC
AI Therapeutics Inc
Altay Therapeutics Inc
Amgen Inc
AntiCancer Inc
APEIRON Biologics AG
Aptadel Therapeutics SL
Atlanthera
Aurora BioPharma Inc
Bayer AG
BioAtla Inc
BioMarck Pharmaceuticals Ltd
Bristol-Myers Squibb Co
CancerVAX Inc
Cebiotex SL
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimerix Inc
Cornerstone Pharmaceuticals Inc
Cothera Bioscience Pty Ltd
Diatheva srl
Edison Oncology Holding Corp
Eisai Co Ltd
Eli Lilly and Co
ENB Therapeutics LLC
EntreChem SL
Esperas Pharma Inc
Exelixis Inc
Fusion Pharmaceuticals Inc
Gate2Brain SL
GenFleet Therapeutics (Shanghai) Inc
Gibson Oncology LLC
Gradalis Inc
GSK plc
Hutchison MediPharma Ltd
ImmunityBio Inc
Inhibrx Inc
Ipsen SA
Iterion Therapeutics Inc
JSK Therapeutics Inc
Lantern Pharma Inc
MacroGenics Inc
Mana Therapeutics Inc
MediaPharma SRL
Merck & Co Inc
NanoValent Pharmaceuticals Inc
Natsar Pharmaceuticals Inc
Nektar Therapeutics
Novartis AG
Ohara Pharmaceutical Co Ltd
Oncology Pharma Inc
Oncomatryx Biopharma SL
OncoTartis Inc
Orgenesis Inc
Orphelia Pharma SAS
Peel Therapeutics Inc
Pfizer Inc
Pharma Mar SA
Prelude Therapeutics Inc
Provectus Biopharmaceuticals Inc
QSAM Therapeutics Inc
Rakovina Therapeutics Inc
Salarius Pharmaceuticals Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shionogi & Co Ltd
Sorrento Therapeutics Inc
Syros Pharmaceuticals Inc
Tarveda Therapeutics Inc
Theranano LLC
Tyme Inc

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Ewing Sarcoma – Overview

Ewing Sarcoma – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Ewing Sarcoma – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ewing Sarcoma – Companies Involved in Therapeutics Development

Ewing Sarcoma – Drug Profiles

Ewing Sarcoma – Dormant Projects

Ewing Sarcoma – Discontinued Products

Ewing Sarcoma – Product Development Milestones

Table

List of Tables

Number of Products under Development for Ewing Sarcoma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Ewing Sarcoma – Dormant Projects, 2022

Ewing Sarcoma – Dormant Projects, 2022 (Contd..1)

Ewing Sarcoma – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Ewing Sarcoma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

What are the key targets of the Ewing Sarcoma pipeline drugs market?

The key targets of the Ewing Sarcoma pipeline drugs market are Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, Mast/Stem Cell Growth Factor Receptor Kit, Vascular Endothelial Growth Factor Receptor 1, DNA, DNA Topoisomerase I, and Fibroblast Growth Factor Receptor 1.
What are the key mechanisms of action of the Ewing Sarcoma pipeline drugs market?

The key mechanisms of action of the Ewing Sarcoma pipeline drugs market are Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, DNA Topoisomerase I Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, DNA Synthesis Inhibitor, and Fibroblast Growth Factor Receptor 1 Inhibitor.
What are the key routes of administration in the Ewing Sarcoma pipeline drugs market?

The key routes of administration in the Ewing Sarcoma pipeline drugs market are Intravenous, Oral, Parenteral, Intradermal, Intravenous Drip, Intratumor, Subcutaneous, and Intraperitoneal.
What are the key molecule types in the Ewing Sarcoma pipeline drugs market?

The molecule types in the Ewing Sarcoma pipeline drugs market are Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Cell Therapy, Gene-Modified Cell Therapy, Fusion Protein, and Oncolytic Virus.
Which are the leading companies in the Ewing Sarcoma pipeline drugs market?

Some of the leading companies in the Ewing Sarcoma pipeline drugs market are Pharma Mar SA, Gradalis Inc, Pfizer Inc, Bristol-Myers Squibb Co, Advenchen Laboratories LLC, Amgen Inc, Bayer AG, and Eisai Co Ltd.

Ewing Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports

Currency USD

Single User

$2,000

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Ewing Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

Assess the relevance of the report
Evaluate the quality of the report
Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Oncology reports

Pharmaceuticals

New

New Drug Approvals and Their Contract Manufacture - 2024 Edition

Pharmaceuticals

New

Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033

Pharmaceuticals

New

Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Ewing Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

Access a live Ewing Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Ewing Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Ewing Sarcoma Pipeline Drugs Market Report Overview

Ewing Sarcoma Pipeline Drugs Market Segmentation by Targets

Ewing Sarcoma Pipeline Drugs Market Segmentation by Mechanism of Actions

Ewing Sarcoma Pipeline Drugs Market Segmentation by Routes of Administration

Ewing Sarcoma Pipeline Drugs Market Segmentation by Molecule Types

Ewing Sarcoma Pipeline Drugs Market - Competitive Landscape

Ewing Sarcoma Pipeline Drugs Market Report Overview

Reasons to Buy

Table of Contents

Table

Figures

Frequently asked questions

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Sample Report

Below is a sample report to understand what you are buying

Related reports